Investor NewsNewsPress Releases
Premier Biomedical’s CEO, William A. Hartman, Returns to Uptick Network “Stock Day” for an Update on Latest Company Developments
El Paso, TX – November 20, 2017 – Premier Biomedical (OTCQB: BIEI) President and CEO, William A. Hartman was again interviewed on the Uptick Network “Stock Day” Podcast. Mr. Hartman overviewed the Company’s Anti-Cancer R&D program and discussed his intent to find a licensee for the technology or investment partner to complete the development of this very promising anti-cancer antibody drug.
Mr. Hartman outlined the unique attributes of Premier Biomedical’s topical pain relief products. In addition to the company’s website at www.painreliefmeds.com, the company has also begun selling its products on Amazon. Mr. Hartman emphasized that the company launched its topical pain relief products with a single product in the first quarter of 2017, a 96-hour skin patch, and has continued to develop and launch additional new products. By year end, the company will have a total of five topical pain relief products available.
Continuing the interview, Mr. Hartman elaborated on Premier Biomedical’s plan to penetrate the professional and collegiate sports medicine arena by adding Carl Eller, President of the NFL retired Players Association, as Marketing and Planning Vice-President. Mr. Eller’s access to retired and active NFL and NCAA players will help the Company penetrate these markets with their expanding array of topical pain relief products. Finally, Mr. Hartman recapped the Company’s plan to expand to large, nation-wide pharmacies, senior living communities, sports activities and off-shore distribution. The topical pain relief products market is estimated to exceed $5 billion within the next five to seven years.
Mr. Hartman stated, “The Company is in the process of developing new products that will ensure our competitive edge in the market. It is projected that 71,000 people in the United States will die from opioid related drug overdoses in 2017. We believe that our all-natural topical pain relief products are a viable alternative to dangerous opioid pain killers. We have attempted to draw attention to our opioid-alternative pain relief products by contacting National and State government agencies engaged in fighting this opioid epidemic.
“Relative to our stock price, our plan for the long term is to get out of debt in order to stop the current over-selling by our lenders in the market and to allow our stock price to achieve its true potential. Overall, I think that our strategy to focus on building the pain management business will be reflected positively in our stock price.”
To listen to the full interview please click here or the following link: http://www.premierbiomedical.com/wp-content/uploads/2017/11/Uptick-Interview-aired-20-Nov-17.mp3
For more information please contact:
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.